

BEST AVAILABLE COPY

Page 1 of 4


<b>FORM PTO-1449 (Modified)</b> Approved for use through 10/19/2002 <b>INFORMATION DISCLOSURE CITATION</b> <b>in an Application</b> (Use several sheets if necessary)	US DEPARTMENT OF COMMERCE US Patent and Trademark Office	Docket No. 50623.325	Application No. 10/632,739
	Applicant Yung-Ming Chen et al.		
	Filing Date August 1, 2003	Group Art Unit 1614 1762	

## U.S. PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
RC	A1	2,072,303	03/02/37	Herrmann et al.	128	335.5	
	A2	4,733,665	03/29/88	Palmaz	128	343	
	A3	4,800,882	01/31/89	Gianturco	128	343	
	A4	4,886,062	12/12/89	Wiktor	128	343	
	A5	4,977,901	12/18/90	Ofstead	128	772	
	A6	4,985,285	01/1991	Ichikawa et al.	428	1.31	
	A7	5,112,457	05/12/92	Marchant	204	165	
	A8	5,328,471	07/12/94	Slepian	604	101	
	A9	5,455,040	10/03/95	Marchant	424	426	
	A10	5,464,650	11/07/95	Berg et al.	427	2.30	
	A11	5,578,073	11/26/96	Haimovich et al.	623	1	
	A12	5,605,696	02/25/97	Eury et al.	424	423	
	A13	5,628,730	05/13/97	Shapland et al.	604	21	
	A14	5,667,767	09/16/97	Greff et al.	424	9.411	
	A15	5,670,558	09/23/97	Onishi et al.	523	112	
	A16	5,700,286	12/23/97	Tartaglia et al.	623	1	
	A17	5,716,981	02/10/98	Hunter et al.	514	449	
	A18	5,756,553	05/1998	Iguchi et al.	514	772.3	
	A19	5,770,301	06/1998	Murai et al.	428	213	
	A20	5,800,392	09/01/98	Racchini	604	96	
	A21	5,824,049	10/20/98	Ragheb et al.	623	1	
	A22	5,830,178	11/03/98	Jones et al.	604	49	
	A23	5,837,313	11/17/98	Ding et al.	427	2.21	

EXAMINER /Rosie Chang/	DATE CONSIDERED 03/14/2007
---------------------------	-------------------------------

EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.



BEST AVAILABLE COPY

Page 2 of 4


<b>FORM PTO-1449 (Modified)</b> Approved for use through 10/1/2002 <b>INFORMATION DISCLOSURE CITATION</b> <b>in an Application</b> (Use several sheets if necessary)	US DEPARTMENT OF COMMERCE US Patent and Trademark Office	Docket No. <b>50623.325</b>	Application No. <b>10/632,739</b>
	Applicant <b>Yung-Ming Chen et al.</b>		
	Filing Date <b>August 1, 2003</b>	Group Art Unit <b>1762</b> <del>1614</del>	

## U.S. PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date If Appropriate
IRC/	A24	5,851,508	12/22/98	Greff et al.	424	9.411	
	A25	5,858,746	01/12/99	Hubbell et al.	435	177	
	A26	5,865,814	02/02/99	Tuch	604	265	
	A27	5,873,904	02/23/99	Ragheb et al.	623	1	
	A28	5,971,954	10/26/99	Conway et al.	604	96	
	A29	5,980,972	11/09/99	Ding	427	2.24	
	A30	5,980,928	11/09/99	Terry	424	427	
	A31	6,010,530	01/04/00	Goicoechea	623	1	
	A32	6,015,541	01/18/00	Greff et al.	424	1.25	
	A33	6,042,875	03/28/00	Ding et al.	427	2.24	
	A34	6,051,648	04/18/00	Rhee et al.	525	54.1	
	A35	6,056,993	05/02/00	Leidner et al.	427	2.25	
	A36	6,060,451	05/09/00	DiMaio et al.	514	13	
	A37	6,080,488	06/27/00	Hostettler et al.	428	423.3	
	A38	6,096,070	08/01/00	Ragheb et al.	623	1	
	A39	6,099,562	08/08/00	Ding et al.	623	1.46	
	A40	6,110,188	08/29/00	Narciso, Jr.	606	153	
	A41	6,113,629	09/05/00	Ken	623	1.1	
	A42	6,120,536	09/19/00	Ding et al.	623	1.43	
	A43	6,120,904	09/19/00	Hostettler et al.	428	423.3	
	A44	6,121,027	09/19/00	Clapper et al.	435	180	
✓	A45	6,129,761	10/10/00	Hubbell	623	11	
IRC/	A46	6,153,252	11/28/00	Hossainy et al.	427	2.3	

EXAMINER <b>/Rosie Chang/</b>	DATE CONSIDERED <b>03/14/2007</b>
----------------------------------	--------------------------------------

EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 809; Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.



<b>FORM PTO-1449 (Modified)</b> Approved for use through 10/31/2002 <b>INFORMATION DISCLOSURE CITATION</b> in an Application (Use several sheets if necessary)	US DEPARTMENT OF COMMERCE US Patent and Trademark Office	Docket No. <b>50623.325</b>	Application No. <b>10/632,739</b>
	Applicant <b>Yung-Ming Chen et al.</b>		
	Filing Date <b>August 1, 2003</b>	Group Art Unit <b>1614</b> <i>1762</i>	

**U.S. PATENT DOCUMENTS**

Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
/RC/	A47	6,165,212	12/26/00	Dereume et al.	623	1.13	
	A48	6,258,121	07/10/01	Yang et al.	623	1.46	
	A49	6,287,588	09/2001	Shih et al.	424	426	
	A50	6,335,029	01/2002	Kamath et al.	424	423	
/RC/	A51	6,368,658	04/2002	Schwarz et al.	427	2.15	

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation	
							Yes	No
/RC/	B1	EP 0 301 856 A2	02/01/89	European				
	B2	WO 91/12846	09/05/91	PCT				
	B3	EP 0 665 023 A1	08/02/95	European				
	B4	WO 96/40174	12/19/96	PCT				
	B5	WO 97/45105	12/04/97	PCT				
	B6	WO 99/01118	01/14/99	PCT				
	B7	WO 99/63981	12/16/99	PCT				
	B8	EP 0 970 711 A2	01/12/00	European				
	B9	WO 00/02599	01/20/00	PCT				
	B10	WO 00/12147	03/09/00	PCT				
	B11	WO 00/64506	11/02/00	PCT				
/RC/	B12	WO 01/01890 A1	01/11/01	PCT				

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, etc.)

/RC/	C1	Miyazawa et al.; Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat; J Cardiovasc Pharmacol 1997; 157
/RC/	C2	Ohsawa et al.; Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty; Am Heart J 1998; 136: 1081

EXAMINER <b>/Rosie Chang/</b>	DATE CONSIDERED <b>03/14/2007</b>
----------------------------------	--------------------------------------

EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

<b>FORM PTO-1449 (Modified)</b> Approved for use through 10/31/2002 <b>INFORMATION DISCLOSURE CITATION</b> <b>in an Application</b> (Use several sheets if necessary)		US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Docket No. <b>50623.325</b>	Application No. <b>10/632,739</b>
				Applicant <b>Yung-Ming Chen et al.</b>	
				Filing Date <b>August 1, 2003</b>	Group Art Unit <del>4614</del> <b>1762</b>
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, etc.)					
/RC/	C3	Shozo Miyazaki, et al.; Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice; 1985; Chem. Pharm. Bull. Vol. 33, No. 6, Pages 2490-2498.			
↓	C4	Peter Barath, M.D. et al.; Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury; February 1989; JACC Vol. 13, No. 2, Page 252 A.			
↓	C5	Taku Shigeno; Prevention of Cerebrovascular Spasm by Bosentan, Novel Endothelin Receptor; 1996; Kanto Rosai Hosp., Kawasaki, 211, Japan; 6(4), 416-421.			
/RC/	C6	Yuji Matsumaru et al.; Embolic Materials For Endovascular Treatment Of Cerebral Lesions; 1997; J. Biomater. Sci. Polymer Edn. Vol. 8, No. 7, Pages 555-569.			
EXAMINER /Rosie Chang/			DATE CONSIDERED <b>03/14/2007</b>		
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

**BEST AVAILABLE COPY**